[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2003256678A8 - Method and composition for treating and preventing hepatitis c infection - Google Patents

Method and composition for treating and preventing hepatitis c infection

Info

Publication number
AU2003256678A8
AU2003256678A8 AU2003256678A AU2003256678A AU2003256678A8 AU 2003256678 A8 AU2003256678 A8 AU 2003256678A8 AU 2003256678 A AU2003256678 A AU 2003256678A AU 2003256678 A AU2003256678 A AU 2003256678A AU 2003256678 A8 AU2003256678 A8 AU 2003256678A8
Authority
AU
Australia
Prior art keywords
infection
treating
composition
preventing hepatitis
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003256678A
Other versions
AU2003256678A1 (en
Inventor
Adrian Hobden
Scott Morham
Kenton Zavitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Publication of AU2003256678A1 publication Critical patent/AU2003256678A1/en
Publication of AU2003256678A8 publication Critical patent/AU2003256678A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003256678A 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis c infection Abandoned AU2003256678A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39726702P 2002-07-19 2002-07-19
US60/397,267 2002-07-19
PCT/US2003/022956 WO2004016738A2 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis c infection

Publications (2)

Publication Number Publication Date
AU2003256678A1 AU2003256678A1 (en) 2004-03-03
AU2003256678A8 true AU2003256678A8 (en) 2004-03-03

Family

ID=31888187

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003256678A Abandoned AU2003256678A1 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis c infection

Country Status (2)

Country Link
AU (1) AU2003256678A1 (en)
WO (1) WO2004016738A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006011686A1 (en) * 2004-07-30 2008-05-01 日本たばこ産業株式会社 Method for screening compound inhibiting cell infection of hepatitis C virus (HCV)
KR100734525B1 (en) * 2005-05-27 2007-07-03 크레아젠 주식회사 Method for Measuring Effectively the Activity of Cytotoxic T Lymphocyte in Human and Out-bred Animals
CN100586474C (en) * 2006-12-28 2010-02-03 北京炎黄麒麟生物技术开发有限公司 Medicine composition, kit and application thereof
CN108707190B (en) * 2018-04-18 2021-07-13 中国科学院武汉病毒研究所 Hog cholera virus NS5B protein fidelity mutant and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461845B1 (en) * 1995-09-27 2002-10-08 Emory University Recombinant hepatitis C virus RNA replicase
CA2312484A1 (en) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds

Also Published As

Publication number Publication date
AU2003256678A1 (en) 2004-03-03
WO2004016738A2 (en) 2004-02-26
WO2004016738A3 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
IL152934A0 (en) Methods and compositions for treating hepatitis c virus
IL174796A0 (en) Methods for treating viral infection using-il-28 and il-29
GB0110288D0 (en) Composition and treatment method
IL164219A0 (en) Method for treating and preventing hyparathyroidism
TWI315986B (en) Compositions and methods for treating or preventing pneumococcal infection
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
AU2002323270A1 (en) Composition and method for treating hiv infection
IL161073A0 (en) Composition and method for treating diabetes
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections
AU2003296963A8 (en) Methods and compositions for treating and preventing ear infections
AU2002324753A1 (en) Composition and method for treating viral infection
ZA200602275B (en) Composition and method for treating bezoar and trichobezoar
AU2002365168A8 (en) Method and composition for treating and preventing hiv infection and aids
AU2003254129A8 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof
PL373593A1 (en) Androgen pharmaceutical composition and method for treating depression
AU2003256678A8 (en) Method and composition for treating and preventing hepatitis c infection
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
HK1046853A1 (en) Method and compositions for treating hepatocellular cancer
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
AU2003303948A8 (en) Compositions and methods for preventing infection
AU2003275069A8 (en) Compositions and methods for preventing infection
HK1069829A1 (en) Surface treatment composition and method
AU2003259198A8 (en) Method and composition for treating and preventing influenza infection and symptoms thereof
AU2001277055A1 (en) Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase